EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Lipid Nanorod-Mediated Codelivery of Inflammasome and STAT3 Inhibitors Attenuates DSS-Induced Colitis

Maharshi Debnath, Mehak Malhotra, Adam Fish, James Forster, Orlin Basarboliev, Ashish Kulkarni

ACS Nano Medicine · 2026-11-09

DOI: 10.1021/acsnanomed.6c00261 ↗
AbstractBibliografische Angaben

Abstract

Abstract Ulcerative colitis (UC) is a complex inflammatory bowel disease driven by the coordinated activation of multiple immune pathways, making single-target therapies often insufficient for disease control. Here, we engineered a dual drug-loaded lipid nanorod platform designed to leverage the enhanced cellular internalization of rod-shaped nanoparticles to simultaneously inhibit complementary inflammatory pathways in dextran sulfate sodium (DSS)-induced colitis, including NLRP3 and AIM2 inflammasome signaling and IL-6/STAT3-mediated inflammation, thereby representing a multimechanistic nanotherapeutic strategy. Therapeutic efficacy was evaluated in an acute DSS-induced colitis mouse model and compared with the corresponding free drug combination and the clinical comparator, 5-aminosalicylic acid (5-ASA). Treatment with the dual drug-loaded nanorods significantly mitigated body weight loss (3-fold lower reduction), preserved colon length, and reduced systemic IL-1β (10-fold) relative to the control groups, while demonstrating superior therapeutic efficacy compared with the corresponding free drug combination. Mechanistic studies revealed simultaneous suppression of NLRP3 and AIM2 inflammasome expression, reduced IL-1β production, and marked inhibition of caspase-1 activation, Gasdermin D cleavage, and STAT3 phosphorylation, indicating coordinated regulation of both inflammasome-driven pyroptosis and IL-6-mediated STAT3 signaling cascades. Collectively, this study establishes dual drug-loaded lipid nanorods as a multipathway immunomodulatory platform for treating experimental colitis and supports coordinated nanotherapy as a promising strategy for inflammatory bowel disease.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →